Conclusions
This study assessed quality of life (QoL) and treatment satisfaction ratings of subjects with moderate plaque psoriasis.
DFD-01 was associated with decreased IGA, TSS, and BSA in adults with moderate plaque psoriasis.
Treatment was associated with improved QoL after 2 weeks of treatment, and subjects reported satisfaction with DFD-01 in both low (3%-10%) and high (>10%) BSA groups.
DFD-01 treatment resulted in better outcomes in subjects with higher BSA involvement at baseline.
Methods
In this open-label, multicenter study, adults with moderate plaque psoriasis (IGA = 3; BSA > 3%, excluding intertriginous areas) applied DFD-01 to affected areas twice daily for 28 days. For each subject, investigators identified 2 target lesions representative of overall disease.
Assessments occurred at days 1 (baseline), 8, 14, and 29. At each visit, disease severity was assessed by IGA, total sign score (TSS) of target lesions, and BSA, and target lesions were photographed.
QoL was evaluated using the Dermatology Life Quality Index (DLQI), a 10-item questionnaire assessing impact of skin disease on quality of life (scores range from 0 (best) to 30 (worst) 1.
Patient satisfaction was evaluated using the Treatment Satisfaction Questionnaire for Medication-Version II (TSQM-II), 9-items assessing effectiveness, side effects, convenience, and global satisfaction, yielding scores ranging from 0 (extremely unsatisfied) to 100 (extremely satisfied).
Primary endpoints were:
(1) Change from baseline in clinical response and QoL at day 14
(2) Treatment Satisfaction at day 14
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